Calcitonin Gene-Related Peptide Receptor Antagonists in the Treatment of Acute Migraine Attacks:A Network Meta-Analysis
Objective To systematically evaluate the effectiveness and safety of different regimens of calcitonin gene-related peptide(CGRP)receptor antagonists in the treatment of acute migraine attacks.Methods The relevant randomized controlled trials(RCTs)in the CNKI,CBM,WanFang,VIP,PubMed,The Cochrane Library and Embase from the inception of these databases to March 31,2023 were searched.The RevMan 5.3 software was used for risk assessment,the Stata 16.0 statistical software was used for network Meta-analysis.Results Nine RCTs were included,involving 9 214 patients and seven intervention measures.The network Meta-analysis showed that the Rimegepant75mg orally disintegrating tablets(ODT)was the optimal choice in the pain disappearance rate after 2 h of medication,pain relief rate after 2 h of medication,sustained pain disappearance rate after 2-24 h of medication,normal functional recovery rate after 2 h of medication,and sustained pain relief rate after 2-24 h of medication;the Ubrogepant50mg oral tablets(TAB)was the optimal choice in the discomfort symptom disappearance rate after 2 h of medication,phonophobia disappearance rate after 2 h of medication,and nausea disappearance rate after 2 h of medication;Zavegepant10mg nasal spray(NS)was the optimal choice in the sustained pain disappearance rate after 2-48 h of medication,sustained pain relief rate after 2-48 h of medication and photophobia disappearance rate after 2 h of medication.Ubrogepant25mgTAB was the optimal choice with the lowest incidence of total adverse reactions,nausea and dizziness.Conclusion Among the three CGRP receptor antagonists,Rimegepant75mgODT is the optimal choice in the treatment of acute migraine attacks,followed by Zavegepant10mgNS,Ubrogepant25mgTAB had the least adverse reactions.
国家科技期刊平台
NSTL
万方数据
维普
